A 4-foot, 2-inch giant fights against NIH cuts that affect her
NEW YORK (PIX11) – In the past three months, the Trump administration has cut the National Institutes of Health's 60,000 research grants by about 800, and counting.
While that represents just over one percent of all NIH research grants, the financial value of those grants far outweighs their number.
Community CloseUp: We're in your neighborhood
So far, more than $2.3 billion in research has been discontinued, or nearly 5% of the NIH's yearly research budget of $47 billion. The Trump administration this month also proposed slashing the NIH budget for next year by nearly half.
This year, meanwhile, it's worth noting that nearly one-third of discontinued grants were for research being carried out in New York.
One New Yorker who's taking an active stance to prevent further cuts points out that the value of the research goes far beyond each project's price tag. Lauren Ruotolo, 48, has been a direct recipient of NIH research, as well as a participant.
'I never thought that I was that different,' Ruotolo said in a recent interview at her apartment, with her Maltipoo, Dutchie, sitting beside her on the sofa.
In many ways, Ruotolo isn't particularly different from any other author, content creator, public speaker or influencer. She did, however, talk about one way in which she stands out.
'I have McCune-Albright syndrome,' she said. 'It's a very rare disease.'
The disease strongly affects bones as they grow, beginning at birth. It creates cysts on bones, which fill with blood.
'At the age of eight, I actually stopped growing,' said Ruotolo about the effect of her condition.
That has not kept her from going anywhere or doing anything. Still, she said that she's fully aware of the challenges that she, and other people with disabilities, face.
It's transformed her from being only a bone disease patient to also becoming an advocate for people with disabilities. She said that one issue in particular is front and center in her advocacy.
'America's crown jewel is biomedical research,' she said, as she pointed out that most of that research is funded by the NIH, which is the largest funder of biomedical research in the world.
'The amount of cuts that have been made is a significant issue,' said Ruotolo. 'At the end of the day, it affects patient care.'
She speaks from personal experience.
'I go and I get poked and prodded in every single test that you can imagine,' she said, describing a process in which she's been involved for more than 15 years.
Ruotolo has been one of a variety of patients in studies and treatment of her rare bone disease at NIH headquarters, in Maryland.
She said that while it's extremely thorough and time-consuming, it's time well spent – all of the time.
'I got to meet children with [McCune-Albright Syndrome],' she said, 'and they got to see me, and I got to tell them that it's going to be okay,' among the many benefits she said that participating in NIH research on her condition has given her and others.
However, during a recent visit to Capitol Hill to advocate for fellow differently-abled Americans, she said, one major development occurred which showed her how under attack many programs are.
'[At] the agency at the NIH that my study is in,' Ruotolo said, '17% of the staff was cut that day.'
It was part of an effort to cut up to 20,000 jobs ordered by Kennedy, whose department, HHS, oversees the NIH.
In explaining the cuts recently, Kennedy said that the point of them is simple.
'We're eliminating redundancies,' he said. 'We're streamlining the agency.'
Most of the grants HHS has cut are related to HIV / AIDS; transgender health; diversity, equity, and inclusion in healthcare; and COVID. Also, while more than two-thirds of the cuts are in states that voted blue in the 2024 election, red states are by no means immune, with the remaining one-third of the reductions.
'It seems like this is just the start,' said Noam Ross, executive director of rOpenSci, a data-science non-profit that has collected and analyzed details from scientists directly affected by the grants' cuts.
'This is going to have huge impacts in the long term,' Ross said about the reductions in research funding. 'These grants are planned out for years, and then can take five years, six years, seven years, to complete this research because it's difficult, complex scientific work.'
'And they can only do that [work],' he continued, 'if the government is going to make a commitment, and keep its promises.'
When the Trump administration does not keep the promises that the federal government made to back research, Ross said, the result is something that affects patients like Ruotolo, as well as the rest of Americans who'll need high-quality healthcare at various points in their lives.
Ruotolo, who describes herself as being no different than anyone else, is able to be no different – despite her rare disease – because of treatments and innovations made through the NIH.
That point is not at all lost on Ruotolo. She said that it's motivated her to increase the number and frequency of her trips to Washington, D.C. to lobby legislators and policymakers, and to try to prevent more cuts.
She said that she's also been speaking out on social media, and on other platforms, as well as writing letters and other content, about preserving and restoring NIH research. She's also encouraging as many people as possible to do the same.
'Because I don't want to just sit at home and be upset and be angry and scream at the TV or just scroll on Instagram,' Ruotolo said. 'I can't just sit down, and not do anything.'
Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
For the latest news, weather, sports, and streaming video, head to PIX11.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
4 hours ago
- Yahoo
GOP's health care plan: We're all going to die, so whatever
If death and taxes are the only certainties, Joni Ernst is here to cut one and fast-track the other. 'We all are going to die," she said. You might think that's a line from a nihilistic French play. Or something a teenage goth said in Hot Topic. Or an epiphany from your stoner college roommate after he watched Interstellar at 3 a.m. But that was actually the Iowa Senator's God-honest response to concerns that slashing Medicaid to achieve President Trump's 'Big Beautiful Bill' would lead to more preventable deaths. The full exchange at a May 30 town hall included one audience member shouting at the stage, 'People will die!' And Ernst responding, 'People are not — well, we all are going to die, so for heaven's sake.' That's not a health care policy — that's a horoscope for the terminally screwed. As you can imagine, the internet didn't love it, because losing your health should not trigger the equivalent of a shrug emoji from someone elected to serve the public good. But rather than walking it back, Ernst leaned in, filming a mock apology in a graveyard because nothing says, 'I care about your future,' like filming next to people who don't have one. Opinion: Nurses are drowning while Braun ignores Indiana's health care crisis Ernst's comments aren't just philosophical musings. She's justifying policy choices that cause real harm. If passed, this bill would, according to the Congressional Budget Office, remove health coverage for up to 7.6 million Americans. That's not just 'we all die someday' territory. That's 'some people will die soon and needlessly.' What makes this even more galling is that the people pushing these cuts have access to high-quality, taxpayer-subsidized healthcare. Congress gets the AAA, platinum, concierge-level government plan. Meanwhile, millions of Americans are told to try their luck with essential oils or YouTube acupuncture tutorials. Honestly, it felt more like performance art than policy: 'Sorry about your grandma getting kicked out of her assisted living facility. Please enjoy this scenic view of her future! LOL!' We're not asking you to defeat death, senator. Death is both inevitable and bipartisan. But there is a broad chasm between dying peacefully at 85 and dying in your 40's because your Medicaid plan disappeared and your GoFundMe didn't meet its goal. Fundamentally, governing is about priorities. A budget is a moral document. When a lawmaker tells you 'we're all going to die' in response to a policy choice, they're telling you 'I've made peace with your suffering as collateral damage.' And if a U.S. Senator can stand in a cemetery and joke about it, you have to wonder — who do our federal legislators think those graves are for? Opinion: Indiana DCS cut foster care in half — and now claims children are safer This isn't just about one comment or one bill. It's about a mindset that treats healthcare as a luxury rather than a right. If death is inevitable, then access to healthcare you can afford is what helps determine how long you have, how comfortably you live, and whether you get to watch your kids grow up. Healthcare isn't about escaping death. It's about dignity and quality of life while we are here. Ernst got one thing right: death will come for us all. But leadership, real leadership, is about helping people live as long and as well as they can before that day comes. You want to make jokes, Senator? Fine. But if your punchline is 'You're all going to die anyway,' don't be surprised when your constituents realize the joke's on them. Kristin Brey is the "My Take" columnist for the Milwaukee Journal Sentinel. This article originally appeared on Milwaukee Journal Sentinel: Joni Ernst films graveyard video after telling sick people "we all die" | Opinion


USA Today
4 hours ago
- USA Today
'I refuse to give up': Michigan researchers, health officials grapple with funding cuts
'I refuse to give up': Michigan researchers, health officials grapple with funding cuts Show Caption Hide Caption Video: MSU breast cancer researcher Jamie Bernard talks about funding uncertainty MSU breast cancer researcher Jamie Bernard talks about federal funding uncertainty on Thursday, May 8, 2025, at her lab in East Lansing. Michigan public health officers say they've had to cut services and lay off workers after the Trump administration slashed funding, affecting their ability to work to stop the spread of disease. Scientists from the University of Michigan and Michigan State University say federal cuts to their research could halt development for new cancer treatments and eviscerate the scientific workforce. Using words like "devastating," "heartbreaking," and "shortsighted," Michigan public health leaders and researchers at the state's largest universities described the effects of President Donald Trump's efforts to slash federal government spending — through executive orders, cuts to federal grants, and stop work orders — and the wide-reaching fallout. Some local health departments have laid off workers and cut back on the services they can provide at regional laboratories and at community and in-school health clinics, and have seen disruptions in their ability to stop the spread of infectious disease, said Norm Hess, executive director of the Michigan Association for Local Public Health. When the U.S. Department of Health and Human Services revoked $11.4 billion in COVID-19-related grants in late March, the effects were felt across Michigan in ways that might not have been anticipated, he said. 'While everyone agrees the emergency response phase of COVID-19 is over, the funding streams created for pandemic response have been supporting laboratories monitoring other diseases around the state, from legionella to tuberculosis to measles, as well as water quality inspections and other sampling work,' Hess said. 'Federal leaders rescinded those grants, clearly thinking it was a responsible way to recover money that was being misspent. Instead, it's a great example of unintended consequences. Everyone agrees government should spend public dollars efficiently and effectively, but it appears they did not check to see what they were actually eliminating when cutting grants that had 'COVID' on the label.' Although Michigan Attorney General Dana Nessel has joined other states in challenging many of the Trump administration's cuts to federal public health and university research funding, including the $11.4 billion in COVID-19-related grants, Hess said it's too risky for local health departments to count on money that may or may not be awarded to them in the end. "You can't turn it off, and then if money comes, turn it back on," he said. Cuts hit research on the science of aging When he took office, Trump pledged to eliminate waste, fraud and abuse in federal spending, and "make America healthy again" by shifting priorities of the nation's top health agencies and taking aim at research and programs that focused on diversity, equity and inclusion. But medical researchers at Michigan State University and the University of Michigan say his administration's abrupt cuts to funding for scientific studies, clinical trials and training programs have all but gutted their life's work and could halt the development of new treatments for diseases like cancer as well as eviscerate the future scientific workforce. University of Michigan psychology professor Toni Antonucci lost the $13 million federal grant that supported her research on health disparities among aging Americans. It focused on minority populations, including African Americans, and comes at a moment in history when the U.S. population is older than it ever has been and is growing increasingly diverse. "I have never thought that politics should be involved in research, and, unfortunately, this is clearly the case here," said Antonucci, who has worked at U-M since the 1970s. "We were focusing on our most vulnerable populations, and I think that's the reason that the money was ... rescinded. "It shows a kind of shortsightedness and, in a way, vindictiveness. ... My focus was on ... how can the social relations that people have improve their health? What kinds of relationships are positive for people or negative for people? How do we increase the positive, and reduce the negative? "What are the kinds of things that universally predict better health, longer longevity? ... The point is, if you know what's influencing different groups, it gives you some insight on how to intervene both with that group and with other groups." Now, she said, that data will be lost. "If a government has policies that they want to enact, regardless of the data, then this is what you do," Antonucci said. "You just make sure there are no data. But just because you don't collect the data, that doesn't mean the association isn't still there." U-M professor: Slashed grants suggest 'you just don't matter' Gary Harper, a U-M professor of health behavior and health equity, learned in late March that his nearly $1.15 million five-year grant from the National Institutes of Health had been rescinded. "It's devastating," said Harper. "I am an openly gay man, and have been involved in activism, research, clinical work, and policy work in the HIV field for 40 years, starting out in 1985 as an old-time activist at a time when we were burying our friends every week. ... This is the first time in the history of my academic career that I've been without federal research or training funds." Harper is co-director of the SOAR at U-M, which stands for Student Opportunities for AIDS/HIV Research. It's a two-year intensive mentoring program that provides HIV-related research opportunities to undergraduate students, propelling them toward graduate school, and, eventually, the HIV research workforce. Many of those students are LGBTQ+ themselves, have disabilities, or come from low-income backgrounds, he said, but Harper noted that the program is open to anyone. "I'm a strong believer that we need to be making sure that we mentor researchers who reflect the communities that are most impacted," Harper said. More: Federal research cuts would rock Michigan economy, halt clinical trials, those affected say More: Trump's budget cuts could cost Michigan universities more than $200 million Discovering that the NIH canceled SOAR's grant funding "ripped me apart," Harper said. "We have one more cohort to get through their senior year." He said he won't let the Trump administration win and cancel the program before they graduate. "Basically, what they're saying is, 'We don't want to spend any money on you because you just don't matter,' " Harper said. " 'Your life has no value.' ... Well, I refuse to give up on them." Harper and SOAR's co-director are scrambling together the money themselves to pay for the final year of the program. Slowly, he said, that is coming together, but his other work through the Adolescent Medicine Trials Network (ATN) for HIV/AIDS Intervention has also been targeted by the federal cuts. A study on transgender youths was canceled, he said, and funding for the leadership group that oversees equity and inclusion in all ATN studies also was eliminated. He also lost grant funding to study gay and bisexual men in Kenya living with HIV. Still, he said, "I'm not going to let this get me down. "I try and show power and strength and resilience to the students, to give them hope that this, too, shall pass. This is a moment in time, but this is not your entire life. ... Your lives do matter. You are special and you are perfect, just the way you are." Breast cancer prevention studies in limbo The Trump administration isn't taking aim solely at research that fits its definition of DEI, said Jamie Bernard, an associate professor of pharmacology and toxicology at Michigan State University. "What I don't really think is being well communicated is that cancer research is also being threatened," said Bernard, who began studying interventions to prevent breast cancer in 2016, when her mother, Pamela O'Brien, was diagnosed with the disease at 61 years old. "This is something that Democrats and Republicans have always supported. In fact, we've come so far in the treatment of breast cancer due to federal funding, we diagnose women earlier. There's lots of options for treatment, and really, this research has saved a lot of lives and brought health care costs down." Her work is now focused on the environmental and lifestyle factors that can increase a woman's risk of getting aggressive breast cancers. "Not all breast cancers are curable, so that's what I really set off to focus on," she said, explaining that her work involves understanding how to kill cancer cells that are resistant to treatment and discovering new drug therapies. Earlier this year, she applied to renew a $2.07 million federal grant funded by the National Institutes of Health along with a new, $2.79 million grant, but both have been held up for months in a cloud of uncertainty. The initial reviews of her grants were postponed but eventually got through the first stage of the process; they now await the second step of review. There remain no guarantees. "How are they going to choose what they fund?" she said. "I don't know what's going to happen, really. So, we are in a time of uncertainty. Grant funding has always been uncertain. It's always been competitive, but there's always been a process and an infrastructure that researchers have relied on." Bernard runs a research lab at MSU, where a team of scientists are working to 'stop breast cancer from ever starting in the first place or prevent it so much that you've delayed it and you die of some other natural cause before you have to deal with cancer," she said. "I am in a place where I don't know if I should be accepting students in the fall. What's my next move? Am I still allowed to study what I've been studying? So it's a confusing time, a frustrating time, a time of high anxiety in our department of pharmacology and toxicology.' Bernard said the NIH canceled a grant for a graduate student from Puerto Rico who is Hispanic, and had applied through a mechanism that provided funding for predoctoral students who are disabled, identify as Black, Hispanic, American Indian or Alaska Native, or who are from socioeconomically disadvantaged backgrounds. "Just simply because she was a minority, the grant mechanism that she applied with, they withdrew it," Bernard said. "The white woman in my lab, her grant is going to be reviewed. ... It's so awful." The work they're doing, she said, "really should be bipartisan, nonpartisan — not even partisan. It's freaking cancer research." Ph.D. student reexamines future in scientific research The political climate is chasing Alex Chapman, a Ph.D. student at MSU who is studying migraines and pain, away from a career in academia. Chapman, 24, who is originally from Richmond, Virginia, secured a federal grant studying a neuropeptide that's upregulated in people with migraines, before Trump took office in January. Many of her friends and colleagues haven't been so lucky. "Science is being so vilified that I'm considering careers in other places or different avenues because it's just hard to see a future in a place that doesn't value science at all," she said. "It's heartbreaking. ... My career options are kind of dwindling, and the more time that passes, the more fellowships and different opportunities just keep becoming defunded," Chapman said, noting that a fellowship she was eyeing through the U.S. Agency for International Development (USAID) has been axed. She considered shifting toward public policy work, helping government leaders understand "why we should fund pain research," but then she attended a symposium and heard a woman who works in public policy speak about the cuts there, too. "She was like, 'This is a great fellowship. It's been defunded. This was an awesome fellowship. It's been defunded,' " Chapman said. When entrepreneur Elon Musk, who headed the new Department of Government Efficiency early in the Trump administration, criticized the use of federal dollars on scientific studies of legumes and aggression in hamsters, Chapman said, it showed that he couldn't see the full impact of the work. "If you just simplify it like that, maybe it does seem silly, but you're looking at the small picture," she said. "The point of research is to zoom out and look at the bigger picture. When you understand the best process of planting beans or why certain strains of corn are more susceptible to different fungi, you help people more effectively and efficiently plant food. This will help us in the face of climate change. "If you understand why a hamster is aggressive after ingesting a certain substance, you understand the role of that substance and how it could potentially affect humans." That small-picture view — and the cuts made because of it — could have generational impacts on the United States and the world, Chapman said. "This isn't just shutting down one study that focuses on hamsters fighting," she said. "It's preventing a new generation of scientists from coming into the (field), which is going to stunt our growth as a nation, which is going to prevent new ideas from happening, which is going to lead to ... horrible damage that would take years, if not decades, to recover. "People are afraid to come out and criticize this because of the way the government has treated them, especially foreign students. When it gets to the point where the government can strike fear in your heart if you speak out against them, especially about something regarding science, it's a very scary place to be." Local public health departments rattled, services cut Nick Derusha, the director and health officer of the LMAS District Health Department, which also includes Luce and Mackinac counties, said his part of the eastern Upper Peninsula has been rattled by a Trump administration stop-work order that means there's no money to run clinics that provide medicine like methadone to help people wean off opioid drugs and reduce the risk of overdose deaths in Alger and Schoolcraft counties. "We take a really holistic approach to that program," Derusha said. "We're not just providing medication-assisted treatment. We have peer recovery coaches. We have community health workers. We have a lot of staff that are there to support them in many other ways, not just the medication. "When funding is abruptly eliminated like that, we can't just drop people off the caseload. We needed to find a way for them to be able to continue to receive services or some type of off-ramp. We worked with the local hospital, and we agreed for three more months, which is kind of nearing the end here, to continue to provide those services, absent the funding. But the long-term ability of us to do that is not likely." In addition, Derusha said the LMAS department lost $512,000 a year to pay for a courier system for its laboratory services. Because the district is so sprawling — it covers four U.P. counties — when test samples need to be shipped to the regional lab in Luce County, ordinary mail often doesn't get them delivered quickly enough. Without the courier system, it means slower results for important public health testing, he said, which could delay treatments and lead to poorer outcomes. The LMAS District Health Department isn't alone. The Mid-Michigan Health Department, which includes Clinton, Gratiot and Montcalm counties, announced in April it will no longer investigate or treat latent tuberculosis infections because of "funding cuts and workforce limitations." Mental health services for school-age children are being cut, too, said Andrea Cole, president of the Ethel and James Flinn Foundation, a Detroit-based nonprofit dedicated to improving the quality, scope, and delivery of mental health services in Michigan. A $1 billion grant was terminated through the Department of Education in late April to pay for in-school social workers, counselors and other mental health professionals — even though 70% of children who receive mental health services get them through their schools, she said. "A lot of the federal cuts were to the most vulnerable and underserved populations," Cole said. "Schools are faced with the possibility of laying off those people that they hired under that grant if they don't have funding to continue it." And the students will be left without that critical mental health support when "they need it more than ever," Cole said. Hess said all of these cuts, along with proposed legislation — the Big, Beautiful Bill Act, which has passed the U.S. House of Representatives and now is under consideration in the U.S. Senate — that would slash Medicaid and Supplemental Nutrition Assistance Program (SNAP) benefits, and a state Senate budget proposal that also seeks to trim funding even more, public health in Michigan could dramatically change. More: Whitmer: Trump's 'big, beautiful bill' could cost Michigan $900 million a year for food stamps More: 700,000 Michigan residents could lose health insurance under Medicaid cuts, report shows "We don't want to give the impression that the sky is falling, and that public health is going to pack up and go home," Hess said. "We've been here for 100 years, and we've seen ups and downs over the years. Health officers are used to kind of making things work, but this is sort of a unique situation. "Community residents are really going to feel this if all of these things that we are watching come to fruition. Public health will not look the same in their communities, in most places." Contact Kristen Shamus: kshamus@ Subscribe to the Detroit Free Press.


Boston Globe
6 hours ago
- Boston Globe
Will Trump's policies kill Massachusetts' life sciences leadership?
Advertisement Although the industry is centered in eastern Massachusetts, there's a statewide benefit from all the tax dollars those businesses and workers pay. Get The Gavel A weekly SCOTUS explainer newsletter by columnist Kimberly Atkins Stohr. Enter Email Sign Up In all, Massachusetts organizations — including universities, research institutes, and hospitals — received $3.5 billion in funding from the National Institutes of Health. Massachusetts-headquartered companies raised $3.26 billion in venture capital funding. Among all drugs in the development pipeline in the United States, 15 percent were being made by companies headquartered in Massachusetts. But actions taken by President Trump and his administration — cutting funding for scientific research and universities, flirting with tariffs, fanning skepticism about vaccines — threaten to devastate the ecosystem. Today, the industry is at a precipice, and uncertainty abounds. Some companies are already feeling the pinch of terminated federal grants, while others are anxious about what might come. Taken together, Trump's policies could force some companies and scientists to take their money, talents, and products overseas. Advertisement Christopher Locher, CEO of Lowell-based Versatope Therapeutics, which develops a platform to deliver vaccines and therapeutics, said he worries the Greater Boston life sciences ecosystem is 'being flushed down the toilet.' For example, Trump is Trump's funding cuts are already having a large impact on some local companies. Part of the problem is the Trump administration isn't only cutting funding, but it's picking which technologies to fund — in some cases apparently based on politics more than science. Take flu vaccines. The Trump administration recently announced a $500 million campaign to fund the development of a universal flu vaccine, which doesn't require annual updates, using technology being worked on But simultaneously, he cut funding for other work on a universal flu vaccine. Versatope Therapeutics got $14 million in NIH funding and spent five years developing a universal flu vaccine. It had approval from the US Food and Drug Administration to begin clinical trials when Trump terminated the contract's remaining $8 million, with the reason given being 'convenience,' Locher said. Trump also Advertisement Company executives say decisions by Trump officials to disinvest in vaccine-related technology — and concerns about whether government will approve new technology — means it's nearly impossible to find private investment funding to replace lost federal dollars. 'We're faced with bankruptcy in the very near future,' Locher said. Ironically, given Trump's stated commitment to bringing businesses back to the United States, one potential option Locher is eyeing is opening a subsidiary abroad. Conducting clinical trials would be cheaper in another country, whether in Europe, Australia, or China, Locher said, and some countries are offering financial incentives to American companies to relocate. Companies also face a potential workforce brain drain. There have been MassBio officials said China has less rigorous — but faster — safety and research protocols than the US. Australia allows a faster timeline for clinical trials. If regulatory approval of medicines is held up because the FDA is understaffed, companies may seek European regulatory approval instead. The loss of talent to foreign countries will be compounded if the pipeline of local university graduates dries up. One draw for life sciences companies to Boston/Cambridge is the presence of elite schools like Harvard and MIT, with their potential for faculty collaboration and skilled graduates. Advertisement Trump is trying to Chip Clark, CEO at Vibrant Biomedicines in Cambridge, said cuts to university research funding both 'shrink the pipeline of great ideas' that form the basis for many biotech startups and translate to fewer available scientists. Clark said the administration's policies 'seem like a deliberate attempt to try to cede scientific leadership to Europe and Japan and Korea and China. ... They will be delighted to capitalize on our talent, technology, and investment capital to make their robust biotech sectors grow and ultimately compete successfully against the US industry,' he said. Don Ingber, founding director of the Wyss Institute for Biologically Inspired Engineering at Harvard University, said he has postdocs with US visas applying for jobs in Europe, and others who were accepted to work at Harvard but are going elsewhere. 'The fact that places like Harvard and MIT and American universities are magnets for the best and brightest from around the world is what's driven our technology economy and certainly the Boston/Cambridge ecosystem,' Ingber said. 'With this uncertainty, I fear we'll lose a generation.' Ingber, who was forced to stop work on two government-funded projects on drugs designed to prevent injury from radiation exposure, compared administration policies to 'eating seed corn' needed to grow crops. Advertisement Trump's vendetta will undermine one of the most vibrant state economies in the country and set back American science by years. And it's not just eastern Massachusetts that will pay a price; the entire country will. As Ingber noted, it might take years to see the impact of medicines or technologies that aren't developed because of these shortsighted cuts. Editorials represent the views of the Boston Globe Editorial Board. Follow us